Merck and Moderna’s Intismeran Autogene Plus Keytruda Meets Phase 3 RFS and DMFS Endpoints in Resected Melanoma

oncodaily - Merck and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial, evaluating intismeran autogene (V940/mRNA-4157) plus Keytruda (pembrolizumab) as adjuvant treatment for patients with completely resected stage IIB-IV […]

AI Summary: Merck and Moderna announced that their mRNA-based melanoma vaccine, given with Keytruda, met key phase‑3 endpoints — reducing recurrence and distant metastasis after resection. The data suggest the vaccine can prime anti‑tumor immunity to prevent relapse, positioning it as a potential adjunct to standard checkpoint inhibition in high‑risk patients.


Experts on personalized mRNA cancer vaccines and implications

Paolo A. Ascierto: Positive Phase 3 KEYTRUDA Results Advance Personalized Melanoma Treatment

6 wks / oncodaily

Marco Donia: First Positive Phase 3 Trial of a Personalized Neoantigen Therapy in Cancer

6 wks / oncodaily

Rob Davis: Individualized Neoantigen Therapy Transforms Adjuvant Melanoma Care

6 wks / oncodaily

INTerpath-001 Trial: Personalized mRNA Cancer Vaccine for Melanoma

6 wks / oncodaily

Will personalised mRNA vaccines transform cancer treatments?

6 wks / newscientist / Michael Le Page


INTerpath-001 trial meets key endpoints

Moderna and Merck Announce Positive Phase 3 INTerpath-001 Results in Melanoma

6 wks / oncodaily

Vaccine breakthrough stops cancer returning in trial

6 wks / bbc

Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning

6 wks / nytimes / Carolyn Y. Johnson

Merck, Moderna claim 'promising' skin cancer vaccine results in key trial

6 wks / medicalxpress

Merck and Moderna’s Intismeran Autogene Plus Keytruda Meets Phase 3 RFS and DMFS Endpoints in Resected Melanoma

6 wks / oncodaily


Moderna pivots to cancer; stock surges

Moderna’s Shift to Cancer Company Lifts Stock Up 177%

6 wks / nytimes / Rebecca Robbins

Noubar Afeyan: Moderna and Merck Announce Positive Phase 3 Results in Melanoma

6 wks / oncodaily

Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test

6 wks / abcnews


All Other Stories

Merck, Moderna Personalized mRNA Cancer Therapy Achieves a First for Melanoma

6 wks / medcitynews / Frank Vinluan




Related Stories

Belzutifan plus lenvatinib outperforms cabozantinib in advanced RCC / 6 wks

First patient enrolled in AACR-ADOPT-GEA gastroesophageal cancer trial / 1 month

Phase 1 trial shows cevostamab activity in relapsed multiple myeloma / 2 months

EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 3 months

Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 3 months

Zanidatamab improves PFS over trastuzumab in HER2 GEA / 4 months

MAGE‑A4/A8 TCR bispecific T‑cell engager shows activity in solid tumors / 4 months

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Long COVID, Weight Loss, Alzheimer's disease, Medicare Advantage (not listed) and look for the RSS link.




↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.